Resources

An alternate form of insulin that is longer lasting may be approved in upcoming years….

The drug pressure-reducing medication olmesartan, brand name Benicar, could increase the time before any kidney problems were evident by 23 percent. But experts are concerned about higher deaths from heart problems….

Valsartan treatment increased glucose-stimulated insulin release and insulin sensitivity in normotensive subjects with IGM….

The effectiveness of KI as a specific blocker of thyroid radioiodine uptake is well established. When administered in the recommended dose, KI is effective in reducing the risk of thyroid cancer in individuals or populations at risk for inhalation or ingestion of radio iodines. KI floods the thyroid with non-radioactive iodine …

Patients headed toward blindness because of diabetic macular edema showed substantial gains in visual acuity after two years of treatment with the angiogenesis inhibitor drug ranibizumab (Lucentis), its manufacturer said….

Amylin Pharmaceuticals, Inc. announced positive results from a mid-stage study of a once-monthly subcutaneous injection of exenatide for the treatment of Type 2 diabetes….

by Jenna Algozzine, Pharm.D. Candidate, University of Florida College of Pharmacy Recombinant human growth hormone (rhGH) is often abused in combination with anabolic steroids to increase muscle strength and athletic performance. The illicit use of androgens is seen not only in athletes, but is now being used by a significant …

Diabetic Neuropathic Disorders, Part 3 John R. White, Jr., PharmD, PA R. Keith Campbell, PharmB, MBA, CDE Travis E. Sonnett, PharmD Adaptation by Matthew Szabo, PharmD (candidate) This week we conclude our three-part excerpt of the ADA/PDR text chapter on Neuropathic Disorders…. 

This graph compares the incidence of type 1 and type 2 diabetes among children and adolescents younger than 20 years by age group and race/ethnicity. In the year 2002–2005, among children younger than 10 years, the estimated rate of new cases of type 1 diabetes was….

  The FDA approved a new angiotensin-receptor blocker (ARB), azilsartan medoxomil (Takeda Pharmaceutical), for the treatment of hypertension in adults. The drug will be available in 80-mg and 40-mg doses, although 80 mg is the recommended dose. The 40-mg dose is available for clinicians who wish to combine the drug …